Aug. 27, 2013
/PRNewswire/ -- Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and the enforcement of federal antitrust laws, is investigating potential claims against the Board of Directors of Chemed Corporation ("Chemed" or the "Company") (NYSE: CHE) concerning possible breaches of fiduciary duty and other violations of law. The investigation concerns actions by Chemed's Board of Directors that have allegedly caused the Company to violate the False Claims Act ("FCA").
May 2, 2013
the Department of Justice announced that it had filed a suit against Chemed for violating the FCA by billing Medicare for excessively costly services and wrongfully admitting patients for hospice care. The government's complaint alleges that Chemed routinely billed Medicare for more costly crisis care services when certain patients did not need crisis care services, often submitted for reimbursement from Medicare for certain services that Chemed subsidiaries did not even provide, and habitually billed Medicare when Chemed subsidiaries provided inappropriate medical care. The complaint alleges that Chemed knowingly caused the submission of false claims to Medicare in violation of the FCA.
Shareholders interested in seeking to recover damages on behalf of Chemed and to implement corporate governance measures designed to prevent future misconduct should contact the firm.
Request more information now by clicking here: www.faruqilaw.com/CHE.
Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action and derivative litigation. The firm is focused on providing exemplary legal services in the areas of securities, shareholder, antitrust and consumer litigation, through all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients.
If you hold Chemed shares and you would like to discuss your legal rights, visit
. You can also contact us by calling
Michael J. Hynes
free at 877-247-4292 or at 215-277-5770 or by sending an e-mail to